FDA
approval
· 2022-10-28
FDA Approved: QBREXZA — Supplemental Application (Journey Medical Corporation)
Summary
The FDA approved a supplemental application for QBREXZA (glycopyrronium) filed by Journey Medical Corporation. This action updates the product's labeling under …
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for QBREXZA (GLYCOPYRRONIUM)